Phase I Trial Results for SL-401, a Novel Cancer Stem Cell (CSC) Targetign Agent, Demonstrate Clinical Efficacy at Tolerable Doses In Patients with Heavily Pre-Treated AML, Poor Risk Elderly AML, and High Risk MDS
WEEKLY GIVEAWAY: 20 UNITS of Xeomin FREE
*Correspondence: Mlanie Morin-Brureau [email protected] This article was submitted to Non-Neuronal Cells, a section of the journal Frontiers in Cellular Neuroscience Disclaimer All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers
Because Ipamorelin is so selective, it tends to have a more favorable side effect profile
It has an order, it has a self order to it
Platforms like RosettaVS have been developed to predict docking poses and binding affinities by using enhanced force fields and flexible receptor models to improve prediction accuracy